Adverse Events from the Treatment of Parkinson's Disease

Neurologic Clinics

Volumn 26, Issue 3 SUPPL., 2008, Pages 65-83

  Chou, Kelvin L ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; AMPHETAMINE; ARIPIPRAZOLE; BROMOCRIPTINE; BUSPIRONE; CAFFEINE; CARBIDOPA; CATECHOL METHYLTRANSFERASE INHIBITOR; CLOZAPINE; DOMPERIDONE; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; METHYLPHENIDATE; METOCLOPRAMIDE; MODAFINIL; MONOAMINE OXIDASE B INHIBITOR; NEUROLEPTIC AGENT; OLANZAPINE; OXYBUTYNIN; PLACEBO; PRAMIPEXOLE; PROCHLORPERAZINE; QUETIAPINE; RISPERIDONE; RIVASTIGMINE; ROPINIROLE; SELEGILINE; TRIMETHOBENZAMIDE; UNINDEXED DRUG; ZIPRASIDONE;

AGRANULOCYTOSIS; BRAIN DEPTH STIMULATION; CLINICAL FEATURE; CLINICAL TRIAL; COMPULSION; CONFUSION; DAYTIME SOMNOLENCE; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG METABOLISM; DRUG WITHDRAWAL; DYSKINESIA; FOOD; FOOD DRUG INTERACTION; HUMAN; HYPERSALIVATION; INSOMNIA; LIVEDO RETICULARIS; LOW DRUG DOSE; MELANOMA; NAUSEA; NOCTURIA; PALLIDOTOMY; PARKINSON DISEASE; PERIPHERAL EDEMA; PRIORITY JOURNAL; PSYCHOSIS; REVIEW; SEDATION; SIDE EFFECT; SLEEP DISORDER; UNSPECIFIED SIDE EFFECT; VOMITING; WAKEFULNESS; WEIGHT GAIN; WEIGHT REDUCTION;

ANTIPARKINSON AGENTS; HUMANS; PARKINSON DISEASE;

EID: 50949128558     PISSN: 07338619     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ncl.2008.05.003     Document Type: Review

References (160)

1. Edwards L.L., Pfeiffer R.F., Quigley E.M., et al. Gastrointestinal symptoms in Parkinson's disease. Mov Disord 6 (1991) 151-156
2. Koller W.C., and Rueda M.G. Mechanism of action of dopaminergic agents in Parkinson's disease. Neurology 50 (1998) S11-S14 [discussion: S44-8]
3. Agid Y., Pollak P., Bonnet A.M., et al. Bromocriptine associated with a peripheral dopamine blocking agent in treatment of Parkinson's disease. Lancet 1 (1979) 570-572
4. Pollak P., Gaio J.M., Hommel M., et al. Acute study of the association of bromocriptine and domperidone in parkinsonism (author's transl). Therapie 36 (1981) 671-676 [in French]
5. Langdon N., Malcolm P.N., and Parkes J.D. Comparison of levodopa with carbidopa, and levodopa with domperidone in Parkinson's disease. Clin Neuropharmacol 9 (1986) 440-447
6. Kolls B.J., and Stacy M. Apomorphine: a rapid rescue agent for the management of motor fluctuations in advanced Parkinson disease. Clin Neuropharmacol 29 (2006) 292-301
7. Ahlskog J.E., and Muenter M.D. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord 16 (2001) 448-458
8. Schrag A., and Schott J.M. Epidemiological, clinical, and genetic characteristics of early-onset parkinsonism. Lancet Neurol 5 (2006) 355-363
9. Grandas F., Galiano M.L., and Tabernero C. Risk factors for levodopa-induced dyskinesias in Parkinson's disease. J Neurol 246 (1999) 1127-1133
10. Pechevis M., Clarke C.E., Vieregge P., et al. Effects of dyskinesias in Parkinson's disease on quality of life and health-related costs: a prospective European study. Eur J Neurol 12 (2005) 956-963
11. Fabbrini G., Brotchie J.M., Grandas F., et al. Levodopa-induced dyskinesias. Mov Disord 22 (2007) 1379-1389 quiz 1523
12. Muenter M.D. Patterns of dystonia in response to L-Dopa therapy for Parkinson's disease. Mayo Clin Proc 52 (1977) 163-174
13. Pahwa R., Factor S.A., Lyons K.E., et al. Practice parameter: treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 66 (2006) 983-995
14. Goetz C.G., Poewe W., Rascol O., et al. Evidence-based medical review update: pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004. Mov Disord 20 (2005) 523-539
15. Luginger E., Wenning G.K., Bosch S., et al. Beneficial effects of amantadine on L-dopa-induced dyskinesias in Parkinson's disease. Mov Disord 15 (2000) 873-878
16. Metman L.V., Del Dotto P., LePoole K., et al. Amantadine for levodopa-induced dyskinesias: a 1-year follow-up study. Arch Neurol 56 (1999) 1383-1386
17. Snow B.J., Macdonald L., McAuley D., et al. The effect of amantadine on levodopa-induced dyskinesias in Parkinson's disease: a double-blind, placebo-controlled study. Clin Neuropharmacol 23 (2000) 82-85
18. Thomas A., Iacono D., Luciano A.L., et al. Duration of amantadine benefit on dyskinesia of severe Parkinson's disease. J Neurol Neurosurg Psychiatry 75 (2004) 141-143
19. Verhagen Metman L., Del Dotto P., van den Munckhof P., et al. Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease. Neurology 50 (1998) 1323-1326
20. Durif F., Debilly B., Galitzky M., et al. Clozapine improves dyskinesias in Parkinson disease: a double-blind, placebo-controlled study. Neurology 62 (2004) 381-388
21. Bonifati V., Fabrizio E., Cipriani R., et al. Buspirone in levodopa-induced dyskinesias. Clin Neuropharmacol 17 (1994) 73-82
22. Goetz C.G., Damier P., Hicking C., et al. Sarizotan as a treatment for dyskinesias in Parkinson's disease: a double-blind placebo-controlled trial. Mov Disord 22 (2007) 179-186
23. Deep Brain Stimulation for Parkinson's Disease Study Group. Deep-brain stimulation of the subthalamic nucleus or the pars interna of the globus pallidus in Parkinson's disease. N Engl J Med 345 (2001) 956-963
24. Visser-Vandewalle V., Van der Linden C., Temel Y., et al. Long-term motor effect of unilateral pallidal stimulation in 26 patients with advanced Parkinson disease. J Neurosurg 99 (2003) 701-707
25. Kleiner-Fisman G., Herzog J., Fisman D.N., et al. Subthalamic nucleus deep brain stimulation: summary and meta-analysis of outcomes. Mov Disord 21 Suppl 14 (2006) S290-S304
26. Arnulf I., Bonnet A.M., Damier P., et al. Hallucinations, REM sleep, and Parkinson's disease: a medical hypothesis. Neurology 55 (2000) 281-288
27. Factor S.A., McAlarney T., Sanchez-Ramos J.R., et al. Sleep disorders and sleep effect in Parkinson's disease. Mov Disord 5 (1990) 280-285
28. Van Hilten J.J., Weggeman M., van der Velde E.A., et al. Sleep, excessive daytime sleepiness and fatigue in Parkinson's disease. J Neural Transm Park Dis Dement Sect 5 (1993) 235-244
29. Brodsky M.A., Godbold J., Roth T., et al. Sleepiness in Parkinson's disease: a controlled study. Mov Disord 18 (2003) 668-672
30. Henderson J.M., Lu Y., Wang S., et al. Olfactory deficits and sleep disturbances in Parkinson's disease: a case control survey. J Neurol Neurosurg Psychiatry 74 (2003) 956-958
31. Hogl B., Seppi K., Brandauer E., et al. Increased daytime sleepiness in Parkinson's disease: a questionnaire survey. Mov Disord 18 (2003) 319-323
32. Arnulf I., Konofal E., Merino-Andreu M., et al. Parkinson's disease and sleepiness: an integral part of PD. Neurology 58 (2002) 1019-1024
33. Fabbrini G., Barbanti P., Aurilia C., et al. Excessive daytime sleepiness in de novo and treated Parkinson's disease. Mov Disord 17 (2002) 1026-1030
34. O'Suilleabhain P.E., and Dewey Jr. R.B. Contributions of dopaminergic drugs and disease severity to daytime sleepiness in Parkinson disease. Arch Neurol 59 (2002) 986-989
35. Hobson D.E., Lang A.E., Martin W.R., et al. Excessive daytime sleepiness and sudden-onset sleep in Parkinson disease: a survey by the Canadian Movement Disorders Group. JAMA 287 (2002) 455-463
36. Razmy A., Lang A.E., and Shapiro C.M. Predictors of impaired daytime sleep and wakefulness in patients with Parkinson disease treated with older (ergot) vs newer (nonergot) dopamine agonists. Arch Neurol. 61 (2004) 97-102
37. Avorn J., Schneeweiss S., Sudarsky L.R., et al. Sudden uncontrollable somnolence and medication use in Parkinson disease. Arch Neurol 62 (2005) 1242-1248
38. Gjerstad M.D., Alves G., Wentzel-Larsen T., et al. Excessive daytime sleepiness in Parkinson disease: is it the drugs or the disease?. Neurology 67 (2006) 853-858
39. Gjerstad M.D., Wentzel-Larsen T., Aarsland D., et al. Insomnia in Parkinson's disease: frequency and progression over time. J Neurol Neurosurg Psychiatry. 78 (2007) 476-479
40. Thornton C., Dore C.J., Elsworth J.D., et al. The effect of deprenyl, a selective monoamine oxidase B inhibitor, on sleep and mood in man. Psychopharmacology (Berl) 70 (1980) 163-166
41. Dhawan V., Dhoat S., Williams A.J., et al. The range and nature of sleep dysfunction in untreated Parkinson's disease (PD). A comparative controlled clinical study using the Parkinson's disease sleep scale and selective polysomnography. J Neurol Sci 248 (2006) 158-162
42. Kumar S., Bhatia M., and Behari M. Sleep disorders in Parkinson's disease. Mov Disord 17 (2002) 775-781
43. Poewe W., and Hogl B. Akathisia, restless legs and periodic limb movements in sleep in Parkinson's disease. Neurology 63 (2004) S12-S16
44. Diederich N.J., Vaillant M., Leischen M., et al. Sleep apnea syndrome in Parkinson's disease. A case-control study in 49 patients. Mov Disord 20 (2005) 1413-1418
45. Aarsland D., Larsen J.P., Lim N.G., et al. Range of neuropsychiatric disturbances in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 67 (1999) 492-496
46. Tandberg E., Larsen J.P., Aarsland D., et al. The occurrence of depression in Parkinson's disease. A community-based study. Arch Neurol 53 (1996) 175-179
47. Mayeux R., Denaro J., Hemenegildo N., et al. A population-based investigation of Parkinson's disease with and without dementia. Relationship to age and gender. Arch Neurol 49 (1992) 492-497
48. Aarsland D., Larsen J.P., Cummins J.L., et al. Prevalence and clinical correlates of psychotic symptoms in Parkinson disease: a community-based study. Arch Neurol 56 (1999) 595-601
49. Parkinson Study Group. Pramipexole vs levodopa as initial treatment for Parkinson disease: a randomized controlled trial. JAMA 284 (2000) 1931-1938
50. Rascol O., Brooks D.J., Korczyn A.D., et al. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group. N Engl J Med 342 (2000) 1484-1491
51. Watts R.L., Jankovic J., Waters C., et al. Randomized, blind, controlled trial of transdermal rotigotine in early Parkinson disease. Neurology 68 (2007) 272-276
52. Frucht S., Rogers J.D., Greene P.E., et al. Falling asleep at the wheel: motor vehicle mishaps in persons taking pramipexole and ropinirole. Neurology 52 (1999) 1908-1910
53. Homann C.N., Wenzel K., Suppan K., et al. Sleep attacks in patients taking dopamine agonists: review. BMJ 324 (2002) 1483-1487
54. Olanow C.W., Schapira A.H., and Roth T. Waking up to sleep episodes in Parkinson's disease. Mov Disord 15 (2000) 212-215
55. Paus S., Brecht H.M., Koster J., et al. Sleep attacks, daytime sleepiness, and dopamine agonists in Parkinson's disease. Mov Disord 18 (2003) 659-667
56. Meindorfner C., Korner Y., Moller J.C., et al. Driving in Parkinson's disease: mobility, accidents, and sudden onset of sleep at the wheel. Mov Disord 20 (2005) 832-842
57. Van den Kerchove M., Jacquy J., Gonce M., et al. Sustained-release levodopa in parkinsonian patients with nocturnal disabilities. Acta Neurol Belg 93 (1993) 32-39
58. Hjort N., Ostergaard K., and Dupont E. Improvement of sleep quality in patients with advanced Parkinson's disease treated with deep brain stimulation of the subthalamic nucleus. Mov Disord 19 (2004) 196-199
59. Adler C.H., Caviness J.N., Hentz J.G., et al. Randomized trial of modafinil for treating subjective daytime sleepiness in patients with Parkinson's disease. Mov Disord 18 (2003) 287-293
60. Hogl B., Saletu M., Brandauer E., et al. Modafinil for the treatment of daytime sleepiness in Parkinson's disease: a double-blind, randomized, crossover, placebo-controlled polygraphic trial. Sleep 25 (2002) 905-909
61. Ondo W.G., Fayle R., Atassi F., et al. Modafinil for daytime somnolence in Parkinson's disease: double blind, placebo controlled parallel trial. J Neurol Neurosurg Psychiatry 76 (2005) 1636-1639
62. Voon V., and Fox S.H. Medication-related impulse control and repetitive behaviors in Parkinson disease. Arch Neurol 64 (2007) 1089-1096
63. Klos K.J., Bower J.H., Josephs K.A., et al. Pathological hypersexuality predominantly linked to adjuvant dopamine agonist therapy in Parkinson's disease and multiple system atrophy. Parkinsonism Relat Disord 11 (2005) 381-386
64. Voon V., Hassan K., Zurowski M., et al. Prevalence of repetitive and reward-seeking behaviors in Parkinson disease. Neurology 67 (2006) 1254-1257
65. Voon V., Hassan K., Zurowski M., et al. Prospective prevalence of pathologic gambling and medication association in Parkinson disease. Neurology 66 (2006) 1750-1752
66. Friedman J.H. Punding on levodopa. Biol Psychiatry 36 (1994) 350-351
67. Avanzi M., Baratti M., Cabrini S., et al. Prevalence of pathological gambling in patients with Parkinson's disease. Mov Disord 21 (2006) 2068-2072
68. Grosset K.A., Macphee G., Pal G., et al. Problematic gambling on dopamine agonists: Not such a rarity. Mov Disord 21 (2006) 2206-2208
69. Weintraub D., Siderowf A.D., Potenza M.N., et al. Association of dopamine agonist use with impulse control disorders in Parkinson disease. Arch Neurol 63 (2006) 969-973
70. Evans A.H., Katzenschlager R., Paviour D., et al. Punding in Parkinson's disease: its relation to the dopamine dysregulation syndrome. Mov Disord 19 (2004) 397-405
71. Miyasaki J.M., Al Hassan K., Lang A.E., et al. Punding prevalence in Parkinson's disease. Mov Disord 22 (2007) 1179-1181
72. Giovannoni G., O'Sullivan J.D., Turner K., et al. Hedonistic homeostatic dysregulation in patients with Parkinson's disease on dopamine replacement therapies. J Neurol Neurosurg Psychiatry 68 (2000) 423-428
73. Pezzella F.R., Colosimo C., Vanacore N., et al. Prevalence and clinical features of hedonistic homeostatic dysregulation in Parkinson's disease. Mov Disord 20 (2005) 77-81
74. Young A.M., Moran P.M., and Joseph M.H. The role of dopamine in conditioning and latent inhibition: what, when, where and how?. Neurosci Biobehav Rev 29 (2005) 963-976
75. Dodd M.L., Klos K.J., Bower J.H., et al. Pathological gambling caused by drugs used to treat Parkinson disease. Arch Neurol 62 (2005) 1377-1381
76. Giladi N., Weitzman N., Schreiber S., et al. New onset heightened interest or drive for gambling, shopping, eating or sexual activity in patients with Parkinson's disease: the role of dopamine agonist treatment and age at motor symptoms onset. J Psychopharmacol 21 (2007) 501-506
77. Driver-Dunckley E.D., Noble B.N., Hentz J.G., et al. Gambling and increased sexual desire with dopaminergic medications in restless legs syndrome. Clin Neuropharmacol 30 (2007) 249-255
78. Evans A.H., and Butzkueven H. Dopamine agonist-induced pathological gambling in restless legs syndrome due to multiple sclerosis. Mov Disord 22 (2007) 590-591
79. Quickfall J., and Suchowersky O. Pathological gambling associated with dopamine agonist use in restless legs syndrome. Parkinsonism Relat Disord 13 (2007) 535-536
80. Tippmann-Peikert M., Park J.G., Boeve B.F., et al. Pathologic gambling in patients with restless legs syndrome treated with dopaminergic agonists. Neurology 68 (2007) 301-303
81. Voon V., Thomsen T., Miyasaki J.M., et al. Factors associated with dopaminergic drug-related pathological gambling in Parkinson disease. Arch Neurol 64 (2007) 212-216
82. Mamikonyan E., Siderowf A.D., Duda J.E., et al. Long-term follow-up of impulse control disorders in Parkinson's disease. Mov Disord 23 1 (2008) 75-80
83. Driver-Dunckley E., Samanta J., and Stacy M. Pathological gambling associated with dopamine agonist therapy in Parkinson's disease. Neurology 61 (2003) 422-423
84. Kurlan R. Disabling repetitive behaviors in Parkinson's disease. Mov Disord 19 (2004) 433-437
85. Miwa H., Morita S., Nakanishi I., et al. Stereotyped behaviors or punding after quetiapine administration in Parkinson's disease. Parkinsonism Relat Disord 10 (2004) 177-180
86. Ardouin C., Voon V., Worbe Y., et al. Pathological gambling in Parkinson's disease improves on chronic subthalamic nucleus stimulation. Mov Disord 21 (2006) 1941-1946
87. Witjas T., Baunez C., Henry J.M., et al. Addiction in Parkinson's disease: impact of subthalamic nucleus deep brain stimulation. Mov Disord 20 (2005) 1052-1055
88. Fenelon G., Mahieux F., Huon R., et al. Hallucinations in Parkinson's disease: prevalence, phenomenology and risk factors. Brain 123 Pt 4 (2000) 733-745
89. Holroyd S., Currie L., and Wooten G.F. Prospective study of hallucinations and delusions in Parkinson's disease. J Neurol Neurosurg Psychiatry. 70 (2001) 734-738
90. Sanchez-Ramos J.R., Ortoll R., and Paulson G.W. Visual hallucinations associated with Parkinson disease. Arch Neurol 53 (1996) 1265-1268
91. Ravina B., Marder K., Fernandez H.H., et al. Diagnostic criteria for psychosis in Parkinson's disease: report of an NINDS, NIMH work group. Mov Disord 22 (2007) 1061-1068
92. Chou K.L., Messing S., Oakes D., et al. Drug-induced psychosis in parkinson disease: phenomenology and correlations among psychosis rating instruments. Clin Neuropharmacol 28 (2005) 215-219
93. Inzelberg R., Kipervasser S., and Korczyn A.D. Auditory hallucinations in Parkinson's disease. J Neurol Neurosurg Psychiatry 64 (1998) 533-535
94. Goetz C.G., Wuu J., Curgian L.M., et al. Hallucinations and sleep disorders in PD: six-year prospective longitudinal study. Neurology 64 (2005) 81-86
95. Marsh L., Williams J.R., Rocco M., et al. Psychiatric comorbidities in patients with Parkinson disease and psychosis. Neurology 63 (2004) 293-300
96. Dewey Jr. R.B., and O'Suilleabhain P.E. Treatment of drug-induced psychosis with quetiapine and clozapine in Parkinson's disease. Neurology 55 (2000) 1753-1754
97. Factor S.A., Molho E.S., Podskalny G.D., et al. Parkinson's disease: drug-induced psychiatric states. Adv Neurol 65 (1995) 115-138
98. Schrag A., Hovris A., Morley D., et al. Caregiver-burden in parkinson's disease is closely associated with psychiatric symptoms, falls, and disability. Parkinsonism Relat Disord 12 (2006) 35-41
99. Aarsland D., Larsen J.P., Tandberg E., et al. Predictors of nursing home placement in Parkinson's disease: a population-based, prospective study. J Am Geriatr Soc 48 (2000) 938-942
100. Goetz C.G., and Stebbins G.T. Risk factors for nursing home placement in advanced Parkinson's disease. Neurology 43 (1993) 2227-2229
101. Factor S.A., Feustel P.J., Friedman J.H., et al. Longitudinal outcome of Parkinson's disease patients with psychosis. Neurology 60 (2003) 1756-1761
102. Goetz C.G., and Stebbins G.T. Mortality and hallucinations in nursing home patients with advanced Parkinson's disease. Neurology 45 (1995) 669-671
103. Chou K.L., and Fernandez H.H. Combating psychosis in Parkinson's disease patients: the use of antipsychotic drugs. Expert Opin Investig Drugs 15 (2006) 339-349
104. Miyasaki J.M., Shannon K., Voon V., et al. Practice parameter: evaluation and treatment of depression, psychosis and dementia in Parkinson's disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 66 (2006) 996-1002
105. Parkinson Study Group. Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson's disease. N Engl J Med 340 (1999) 757-763
106. Pollak P., Tison F., Rascol O., et al. Clozapine in drug induced psychosis in Parkinson's disease: a randomized, placebo controlled study with open follow up. J Neurol Neurosurg Psychiatry 75 (2004) 689-695
107. Fernandez H.H., Trieschmann M.E., Burke M.A., et al. Long-term outcome of quetiapine use for psychosis among Parkinsonian patients. Mov Disord 18 (2003) 510-514
108. Reddy S., Factor S.A., Molho E.S., et al. The effect of quetiapine on psychosis and motor function in parkinsonian patients with and without dementia. Mov Disord 17 (2002) 676-681
109. Merims D., Balas M., Peretz C., et al. Rater-blinded, prospective comparison: quetiapine versus clozapine for Parkinson's disease psychosis. Clin Neuropharmacol 29 (2006) 331-337
110. Morgante L., Epifanio A., Spine E., et al. Quetiapine and clozapine in parkinsonian patients with dopaminergic psychosis. Clin Neuropharmacol 27 (2004) 153-156
111. Ondo W.G., Tintner R., Voung K.D., et al. Double-blinded, placebo-controlled, unforced titration parallel trial of quetiapine for dopaminergic-induced hallucinations in Parkinson's disease. Mov Disord 20 (2006) 958-963
112. Rabey J.M., Prokhorov T., Miniovitz A., et al. Effect of quetiapine in psychotic Parkinson's disease patients; a double-blinded labeled study of 3 months' duration. Mov Disord 22 (2007) 313-318
113. Breier A., Sutton V.K., Feldman P.D., et al. Olanzapine in the treatment of Dopamimetic-induced psychosis in patients with Parkinson's disease. Biol Psychiatry 52 (2002) 438-445
114. Goetz C.G., Blasucci L.M., Leurgans S., et al. Olanzapine and clozapine: comparative effects on motor function in hallucination PD patients. Neurology 55 (2000) 789-794
115. Ford B., Lynch T., and Greene P. Risperidone in Parkinson's disease. Lancet 344 8923 (1994) 681
116. Rich S.S., Friedman J.H., and Ott B.R. Risperidone versus clozapine in the treatment of psychosis in six patients with Parkinson's disease and other akinetic-rigid syndromes. J Clin Psychiatry 56 12 (1995) 556-559
117. Meco G., Alessandri A., Giustini P., et al. Risperidone in levodopa-induced psychosis in advanced Parkinson's disease: an open-label, long-term study. Mov Disord 12 4 (1997) 610-612
118. Leopold N.A. Risperidone treatment of drug-related psychosis in patients with Parkinsonism. Mov Disord 15 2 (2000) 301-304
119. Mohr E., Mendis T., Hildebrand K., et al. Risperidone in the treatment of dopamine-induced psychosis in Parkinson's disease: an open pilot trial. Mov Disord 15 6 (2000) 1230-1237
120. Fernandez H.H., Trieschmann M.E., and Friedman J.H. Aripiprazole for drug-induced psychosis in Parkinson disease: preliminary experience. Clin Neuropharmacol 27 1 (2004) 4-5
121. Friedman J.H., Berman R.M., Goetz C.G., et al. Open-label flexible dose pilot study to evaluate the safety and tolerability of aripiprazole in patients with psychosis associated with Parkinson's disease. Mov Disord 21 12 (2006) 2078-2081
122. Emre M., Aarsland D., Albanese A., et al. Rivastigmine for dementia associated with Parkinson's disease. N Engl J Med 351 (2004) 2509-2518
123. Pearce L.A., Waterbury L.D., and Green H.D. Amantadine hydrochloride: alteration in peripheral circulation. Neurology 24 (1974) 46-48
124. Blackard W.G. Edema-an infrequently recognized complication of bromocriptine and other ergot dopaminergic drugs. Am J Med 94 (1993) 445
125. Bianchi M., and Castiglioni M.G. Refractory generalized edema: an infrequent complication of long-term pergolide treatment for Parkinson disease. Clin Neuropharmacol 28 (2005) 245-246
126. Varsano S., Gershman M., and Hamaoui E. Pergolide-induced dyspnea, bilateral pleural effusion and peripheral edema. Respiration 67 (2000) 580-582
127. Biglan K.M., Holloway Jr. R.G., McDermott M.P., et al. Risk factors for somnolence, edema, and hallucinations in early Parkinson disease. Neurology 69 (2007) 187-195
128. Kleiner-Fisman G., and Fisman D.N. Risk factors for the development of pedal edema in patients using pramipexole. Arch Neurol 64 (2007) 820-824
129. Tan E.K., and Ondo W. Clinical characteristics of pramipexole-induced peripheral edema. Arch Neurol 57 (2000) 729-732
130. Schrag A.E., Brooks D.J., Brunt E., et al. The safety of ropinirole, a selective nonergoline dopamine agonist, in patients with Parkinson's disease. Clin Neuropharmacol 21 (1998) 169-175
131. Holloway R.G., Shoulson I., Fahn S., et al. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Arch Neurol 61 (2004) 1044-1053
132. Olsen J.H., Friis S., and Frederiksen K. Malignant melanoma and other types of cancer preceding Parkinson disease. Epidemiology 17 (2006) 582-587
133. Olsen J.H., Friis S., Frederiksen K., et al. Atypical cancer pattern in patients with Parkinson's disease. Br J Cancer 92 (2005) 201-205
134. Zanetti R., Loria D., and Rosso S. Melanoma, Parkinson's disease and levodopa: causal or spurious link? A review of the literature. Melanoma Res 16 (2006) 201-206
135. Jansson B., and Jankovic J. Low cancer rates among patients with Parkinson's disease. Ann Neurol 17 (1985) 505-509
136. Moller H., Mellemkjaer L., McLaughlin J.K., et al. Occurrence of different cancers in patients with Parkinson's disease. BMJ 310 (1995) 1500-1501
137. Skibba J.L., Pinckley J., Gilbert E.F., et al. Multiple primary melanoma following administration of levodopa. Arch Pathol 93 (1972) 556-561
138. Kable E.P., Favier D., and Parsons P.G. Sensitivity of human melanoma cells to L-dopa and DL-buthionine (S,R)-sulfoximine. Cancer Res 49 (1989) 2327-2331
139. Fiala K.H., Whetteckey J., and Manyam B.V. Malignant melanoma and levodopa in Parkinson's disease: causality or coincidence?. Parkinsonism Relat Disord 9 (2003) 321-327
140. Siple J.F., Schneider D.C., Wanlass W.A., et al. Levodopa therapy and the risk of malignant melanoma. Ann Pharmacother 34 (2000) 382-385
141. Constantinescu R., Romer M., and Kieburtz K. Malignant melanoma in early Parkinson's disease: the DATATOP trial. Mov Disord 22 (2007) 720-722
142. Olsen J.H., Tangerud K., Wermuth L., et al. Treatment with levodopa and risk for malignant melanoma. Mov Disord 22 (2007) 1252-1257
143. Frigerio R., Elbaz A., Sanft K.R., et al. Education and occupations preceding Parkinson disease: a population-based case-control study. Neurology 65 (2005) 1575-1583
144. Elwood J.M., Whitehead S.M., Davison J., et al. Malignant melanoma in England: risks associated with naevi, freckles, social class, hair colour, and sunburn. Int J Epidemiol 19 (1990) 801-810
145. Driver J.A., Logroscino G., Buring J.E., et al. A prospective cohort study of cancer incidence following the diagnosis of Parkinson's disease. Cancer Epidemiol Biomarkers Prev 16 (2007) 1260-1265
146. Abbott R.A., Cox M., Markus H., et al. Diet, body size and micronutrient status in Parkinson's disease. Eur J Clin Nutr 46 (1992) 879-884
147. Chen H., Zhang S.M., Hernan M.A., et al. Weight loss in Parkinson's disease. Ann Neurol 53 (2003) 676-679
148. Uc E.Y., Struck L.K., Rodnitzky R.L., et al. Predictors of weight loss in Parkinson's disease. Mov Disord 21 (2006) 930-936
149. Beyer P.L., Palarino M.Y., Michalek D., et al. Weight change and body composition in patients with Parkinson's disease. J Am Diet Assoc 95 (1995) 979-983
150. Vardi J., Oberman Z., Rabey I., et al. Weight loss in patients treated long-term with levodopa. Metabolic aspects. J Neurol Sci 30 (1976) 33-40
151. Lorefalt B., Ganowiak W., Palhagen S., et al. Factors of importance for weight loss in elderly patients with Parkinson's disease. Acta Neurol Scand 110 (2004) 180-187
152. Markus H.S., Tomkins A.M., and Stern G.M. Increased prevalence of undernutrition in Parkinson's disease and its relationship to clinical disease parameters. J Neural Transm Park Dis Dement Sect 5 (1993) 117-125
153. Davies K.N., King D., and Davies H. A study of the nutritional status of elderly patients with Parkinson's disease. Age Ageing 23 (1994) 142-145
154. Markus H.S., Cox M., and Tomkins A.M. Raised resting energy expenditure in Parkinson's disease and its relationship to muscle rigidity. Clin Sci (Lond). 83 (1992) 199-204
155. Levi S., Cox M., Lugon M., et al. Increased energy expenditure in Parkinson's disease. BMJ 301 (1990) 1256-1257
156. Toth M.J., Fishman P.S., and Poehlman E.T. Free-living daily energy expenditure in patients with Parkinson's disease. Neurology 48 (1997) 88-91
157. Lang A.E., Lozano A., Tasker R., et al. Neuropsychological and behavioral changes and weight gain after medial pallidotomy. Ann Neurol 41 (1997) 834-836
158. Ondo W.G., Ben-Aire L., Jankovic J., et al. Weight gain following unilateral pallidotomy in Parkinson's disease. Acta Neurol Scand 101 (2000) 79-84
159. Vitek J.L., Bakay R.A., Freeman A., et al. Randomized trial of pallidotomy versus medical therapy for Parkinson's disease. Ann Neurol 53 (2003) 558-569
160. Moro E., Scerrati M., Romito L.M., et al. Chronic subthalamic nucleus stimulation reduces medication requirements in Parkinson's disease. Neurology 53 (1999) 85-90